Woolworths Proposes To Buy Australian Pharmaceutical For A$1.75/shr

Woolworths Group (WOW.AX)) said Thursday that it has proposed to buy Australian Pharmaceutical Industries Limited or API for A$1.75 per API share in cash or total equity value of A$872 million.

The proposed offer price represents a premium of 20 cents per share or 12.9% over the price agreed between API and Wesfarmers under the scheme implementation deed announced on 8 November 2021.

Woolworths noted that the Board of API has determined that the Woolworths proposal is, or is reasonably likely to be, a superior proposal, as defined in the Wesfarmers Scheme Implementation Deed. Woolworths Group will engage constructively with API to quickly finalise its due diligence enquiries.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Covid vaccine makers Pfizer Inc. and BioNTech SE announced a new $3.2 billion vaccine supply deal with the U.S. Government, as the country is bracing for a Covid outbreak this fall. Under the deal, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg) of Pfizer -BioNTech covid vaccines initially. The order may include adult Omicron-adapted COVID-19 vaccines. Samsung Electronics Co. has started the initial mass production of 3-nanometer or nm chips, which is considered as the most advanced chip in the world. In its move, the South Korean tech major beats rival Taiwan Semiconductor Manufacturing Co., the world's largest chip manufacturer, which is reportedly in the process to build one. Bryant Ranch Prepack Inc. is recalling certain Morphine Sulfate Extended-Release Tablets citing incorrect labeling, the U.S. Food and Drug Administration said. The recall involves one lot of Morphine Sulfate 30 mg Extended-Release tablets, and one lot of Morphine Sulfate 60 mg Extended-Release tablets to the consumer level.
Follow RTT